Ventyx Biosciences (NASDAQ:VTYX) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen has upgraded Ventyx Biosciences (NASDAQ:VTYX) from a "sell" rating to a "hold" rating in a recent report.
• The stock has seen a remarkable increase of 19.1%, opening at $2.81 with a market cap of approximately $199.96 million.
• Ventyx Biosciences reported a loss of ($0.38) earnings per share for the last quarter, better than the estimated loss of ($0.45).

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock traded up $0.45 during trading hours on Friday, hitting $2.81. 1,892,363 shares of the stock traded hands, compared to its average volume of 997,980. The firm's 50-day moving average price is $2.55 and its two-hundred day moving average price is $1.82. Ventyx Biosciences has a one year low of $0.78 and a one year high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. As a group, analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ventyx Biosciences

Several large investors have recently made changes to their positions in VTYX. American Century Companies Inc. lifted its holdings in shares of Ventyx Biosciences by 12.4% during the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock valued at $147,000 after purchasing an additional 7,414 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Ventyx Biosciences by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company's stock worth $3,095,000 after purchasing an additional 21,337 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Ventyx Biosciences by 23.3% in the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after purchasing an additional 7,768 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Ventyx Biosciences by 99.1% in the 4th quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock worth $1,368,000 after buying an additional 310,800 shares during the period. Finally, Barclays PLC boosted its holdings in Ventyx Biosciences by 14.2% in the 4th quarter. Barclays PLC now owns 91,669 shares of the company's stock worth $200,000 after buying an additional 11,374 shares during the period. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.